US govt requests "rapid" drug action from China

5 August 2007

The US Secretary of Health and Human Services, Michael Leavitt, called on the Chinese government to ensure "rapid action to accomplish certain goals related to the safety of food and drugs." He added that the DHHS had "emphasized the need for three things: to have better cooperation, to have better information, and to have the Chinese devise and enforce regulations that we can understand, with which we agree and in which we feel confident."

The statement by Mr Leavitt was made on the occasion of USA-China bilateral meetings on food and drug safety, following a recent spate of incidents involving imported products from China, as well as the US Food and Drug Administration's investigation of counterfeit drug materials in Panama (Marketletters passim) where several hundred people were reportedly taken ill or died, due to fake glycerin from China in locally-manufactured cough syrup.

US media reports have highlighted the growing number of drugs and health supplements, such as vitamin tablets, that are imported from China. In an effort to boost local and international confidence, the Chinese government is reforming the State Food and Drug Administration and even recently executed its former Director (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight